A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

Forskningsoutput: TidskriftsbidragPublicerat konferensabstract

Standard

A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. / Margolin, S; Carlsson, L; Hellström, M; Karlsson, P; Lidbrink, E; Linderholm, B; Lindman, H; Malmström, Per; Sköld Pettersson, D; Bergh, J.

I: European Journal of Cancer Supplements, Vol. 6, Nr. 7, 2008, s. 116-117.

Forskningsoutput: TidskriftsbidragPublicerat konferensabstract

Harvard

APA

CBE

MLA

Vancouver

Author

RIS

TY - JOUR

T1 - A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

AU - Margolin, S

AU - Carlsson, L

AU - Hellström, M

AU - Karlsson, P

AU - Lidbrink, E

AU - Linderholm, B

AU - Lindman, H

AU - Malmström, Per

AU - Sköld Pettersson, D

AU - Bergh, J

PY - 2008

Y1 - 2008

U2 - 10.1016/S1359-6349(08)70548-2

DO - 10.1016/S1359-6349(08)70548-2

M3 - Published meeting abstract

VL - 6

SP - 116

EP - 117

JO - European Journal of Cancer Supplements

JF - European Journal of Cancer Supplements

SN - 1359-6349

IS - 7

T2 - EBCC-6, European Breast Cancer Conference, 2008

Y2 - 14 April 2008 through 19 April 2008

ER -